Sun Pharma agrees to supply at MFN pricing to U.S. medicaid programmes
The U.S. is the company’s largest market for innovative medicines and a cornerstone of its long-term growth strategy, generating approximately 27% of the company’s global revenue.
Original Source
Read the full article at Thehindu →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.